Comparison
BPC-157 vs GHK-Cu
Side-by-side of BPC-157 and GHK-Cu. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
GHK-Cu
GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper) is a topical copper peptide. Trials show fine-line and wound-healing gains; injectable longevity claims rem.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
GHK-Cu
- •Endogenous tripeptide that binds copper(II); plasma levels decline ~60% from age 20 to 60
- •Topical RCTs show improvement in skin firmness, fine lines, and barrier function over 12 weeks
- •Wound-healing models report accelerated re-epithelialization in diabetic and aged skin
- •Pickart gene-expression analyses show reset of >4000 genes toward a younger expression profile in cell culture
- •Anecdotal subcutaneous longevity protocols use 1 to 3 mg daily; no human longevity RCTs exist
- •Hair-growth claims rest on small open-label trials and topical scalp formulations
Side-by-side
| Attribute | BPC-157 | GHK-Cu |
|---|---|---|
| Category | peptide | peptide |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | Copper Peptide, Glycyl-L-histidyl-L-lysine copper, GHK |
| Half-life (hr) ↗ | 4 | 0.5 |
| Typical dose (mg) ↗ | 0.25 | 2 |
| Dosing frequency | daily (anecdotal protocols) | daily |
| Routes | subcutaneous, intramuscular, oral | topical, subcutaneous |
| Onset (hr) | - | 24 |
| Peak (hr) | - | 168 |
| Molecular weight | - | 340.85 |
| Molecular formula | C62H98N16O22 | C14H24N6O4 (GHK alone); C14H22CuN6O4 with Cu(II) |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Tripeptide that chelates Cu(II) and delivers it to copper-dependent enzymes (lysyl oxidase, superoxide dismutase). Modulates expression of >4000 genes toward a younger profile in fibroblast culture, including upregulation of decorin and downregulation of pro-inflammatory cytokines. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Topical cosmetics legal in most jurisdictions; injectable form not FDA approved for any indication; research-use-only grey market |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Topical OTC (cosmetic); injectable not FDA approved; research-chemical status |
| Pregnancy | Insufficient data | Insufficient data; topical use likely low-risk; injectable not recommended |
| CAS | 137525-51-0 | 49557-75-7 |
| PubChem CID | 9941957 | 73587 |
| Wikidata | Q4835418 | Q3104638 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
GHK-Cu
Common side effects
- mild erythema at topical site
- transient itch
- blue-green discoloration of injection site (copper)
- rare contact dermatitis
Contraindications
- copper allergy
- Wilson disease
- open wound near injection site (caution)
- pregnancy (no data)
Interactions
- topical retinoids: additive irritation; alternate days or apply at different times(minor)
- topical vitamin C (ascorbic acid): ascorbate reduces Cu(II) to Cu(I), which can destabilize the GHK-Cu complex; separate by 30 minutes(minor)
Which Should You Take?
GHK-Cu comes out ahead for most readers on the criteria we weight: 4 catalogued goals, research-only / gray-market sourcing, with a Tier-B outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is skin health, pick GHK-Cu.
- → If your priority is wound healing, pick GHK-Cu.
Edge case: If you cannot self-administer injections, BPC-157 is the only oral option in this pair.
Default choice: GHK-Cu. Wider use case, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and GHK-Cu?
BPC-157 and GHK-Cu differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or GHK-Cu?
BPC-157 half-life is 4 hours; GHK-Cu half-life is 0.5 hours.
Can you stack BPC-157 with GHK-Cu?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper